Metagenomi, Inc. Common Stock (MGX)

Metagenomi, Inc. Common Stock at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Metagenomi, Inc. Common Stock (MGX) is a Biotechnology company based in US with a market capitalization of $51.6M. Revenue declined 51.8% year-over-year and free cash flow was negative at -$89.5M. This page tracks MGX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 202 employees · IPO Apr 6, 2006

Valuation

Valuation & price

$1.31as of May 17, 2026· -60.9% vs 52w high

P/E ratio

Latest-FY diluted EPS

0.33

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$3.33$2.25$1.17Jul 25Dec 25Jul 26
$1.1452-week range$3.35
Loading valuation history…

Fundamentals

Key fundamentals

$51.6M

Market cap

-51.8%

Revenue growth (YoY)

78.9%

Gross margin

-$89.5M

Free cash flow (USD)

-$120.1M

Net debt

Net cash position

-0.5%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20212025

$243K$25.2M

Free cash flow by year

20212025

$21.4M-$89.5M

Gross margin by year

20212025

-59.3%78.9%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 11, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventJun 10, 2026Filing

    Director Resignation and Election

  • 8-K eventMay 11, 2026Filing

    Earnings Release

  • Quarterly reportMay 11, 2026Filing

    10-Q Filed

Questions

Frequently asked questions

What is Metagenomi, Inc. Common Stock's market cap?

Metagenomi, Inc. Common Stock (MGX) has a market capitalization of $51.6M.

What is MGX's P/E ratio?

A meaningful P/E ratio is not available for MGX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is MGX's price-to-book (P/B) ratio?

MGX trades at 0.33 times book value per share.

Are insiders buying MGX stock?

SEC Form 4 filings show no open-market insider buys at Metagenomi, Inc. Common Stock in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.